<DOC>
	<DOC>NCT00163397</DOC>
	<brief_summary>The aim of the study is to investigate the efficacy of ciclesonide versus budesonide on lung function, symptoms and use of rescue medication in patients with asthma. Ciclesonide and budesonide will be inhaled once daily at one dose level each. The study duration consists of a baseline period (1 to 4 weeks) and a treatment period (12 weeks). The study will provide further data on safety and tolerability of ciclesonide.</brief_summary>
	<brief_title>Efficacy of Ciclesonide Versus Budesonide in Patients With Asthma (18 to 75 y) (BY9010/M1-137)</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Main During the last 4 weeks prior to baseline, treatment with an inhaled steroid (dosage: up to 250 mcg fluticasone propionate or equivalent) FEV1 80 105% of predicted Healthy with the exception of asthma Written informed consent has been obtained Outpatients Patients who have a history of persistent bronchial asthma for at least 6 months Main Concomitant severe diseases or diseases which are contraindications for the use of inhaled steroids Concomitant COPD (i.e. chronic bronchitis or emphysema) and/or other relevant lung diseases causing alternating impairment in lung function An asthma exacerbation or an infection of the lower airways prior to entry into the baseline period Pregnancy Intention to become pregnant during the course of the study Breast feeding Lack of safe contraception Patient is current smoker with 10 or more packyears Patient is exsmoker with 10 or more packyears</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Ciclesonide</keyword>
	<keyword>Budesonide</keyword>
</DOC>